Cancer Immunol Res. 2022 Aug 3;10(8):919. doi: 10.1158/2326-6066.CIR-22-0386.
T-cell receptors (TCR) are an antigen receptor class that can uniquely respond to epitopes resulting from cytosolic and intranuclear proteins. In this issue, Kim and colleagues report the first successful application of TCR gene therapy targeting a shared, or public, neoantigen resulting from a TP53 hotspot mutation. These results establish clinical proof of concept that an off-the-shelf TCR targeting a recurrent mutation in a molecular driver of oncogenesis can benefit patients with metastatic cancer. See related article by Kim et al., p. 932 (4) .
T 细胞受体 (TCR) 是一种抗原受体类别，能够特异性地对来自细胞质和核内蛋白的表位做出反应。在本期中，Kim 及其同事报告了 TCR 基因治疗靶向 TP53 热点突变导致的共享或公共新抗原的首次成功应用。这些结果为临床概念验证提供了依据，即针对致癌分子驱动因素中的复发性突变的现成 TCR 靶向治疗可以使转移性癌症患者受益。另见 Kim 等人的相关文章，第 932 页（4）。
